Aravax Appoints Aled Williams as CBO to Spearhead International Expansion of Peanut Allergy Therapy PVX108
• Aravax appointed Aled Williams as Chief Business Officer to bolster its international presence and strategic partnerships.
• Williams will focus on expanding the Aravax portfolio and advancing the asset strategy, leveraging his 25 years of biotech and pharma experience.
• The appointment supports the Phase 2 development of PVX108, Aravax's lead immunotherapy for peanut allergy, designed for safer and more targeted treatment.
• Aravax aims to establish itself as a leader in food allergy treatments through innovative immunotherapies and strategic global outreach.
© Copyright 2025. All Rights Reserved by MedPath